1. The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics.
- Author
-
Muslimov, Albert, Tereshchenko, Valeriy, Shevyrev, Daniil, Rogova, Anna, Lepik, Kirill, Reshetnikov, Vasiliy, and Ivanov, Roman
- Subjects
TRANSMISSIBLE tumors ,IMMUNE system ,MOLECULAR biology ,GENOME editing ,GENE therapy ,MESSENGER RNA ,NUCLEIC acids - Abstract
Advances in molecular biology have revolutionized the use of messenger RNA (mRNA) as a therapeutic. The concept of nucleic acid therapy with mRNA originated in 1990 when Wolff et al. reported successful expression of proteins in target organs by direct injection of either plasmid DNA or mRNA. It took decades to bring the transfection efficiency of mRNA closer to that of DNA. The next few decades were dedicated to turning in vitro-transcribed (IVT) mRNA from a promising delivery tool for gene therapy into a full-blown therapeutic modality, which changed the biotech market rapidly. Hundreds of clinical trials are currently underway using mRNA for prophylaxis and therapy of infectious diseases and cancers, in regenerative medicine, and genome editing. The potential of IVT mRNA to induce an innate immune response favors its use for vaccination and immunotherapy. Nonetheless, in non-immunotherapy applications, the intrinsic immunostimulatory activity of mRNA directly hinders the desired therapeutic effect since it can seriously impair the target protein expression. Targeting the same innate immune factors can increase the effectiveness of mRNA therapeutics for some indications and decrease it for others, and vice versa. The review aims to present the innate immunity-related 'barriers' or 'springboards' that may affect the development of immunotherapies and non-immunotherapy applications of mRNA medicines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF